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Abstract 
 
The purpose of this study was to test the feasibility of undertaking a full population investigation into 
the prevalence, incidence, and persistence of oral Human Papilloma Virus (HPV) in Scotland via 
dental settings. Male and female patients aged 16-69 years were recruited by Research Nurses in 3 
primary care and dental outreach teaching centres and 2 General Dental Practices (GDPs), and by 
Dental Care Teams in 2 further GDPs. Participants completed a questionnaire (via an online tablet 
computer or paper) with socioeconomic, lifestyle, and sexual history items; and were followed up at 
6-months for further questionnaire through appointment or post/online. Saline oral gargle/rinse 
samples, collected at baseline and follow-up, were subject to molecular HPV genotyping centrally. 
1213 dental patients were approached and 402 individuals consented (participation rate 33.1%). 390 
completed the baseline questionnaire and 380 provided a baseline oral specimen. Follow-up rate 
was 61.6% at 6 months. While recruitment was no different in Research Nurse vs Dental Care Team 
models the Nurse model ensured more rapid recruitment. There were relatively few missing 
responses in the questionnaire and high levels of disclosure of risk behaviours (99% answered some 
of the sexual history questions). Data linkage of participant data to routine health records including 
HPV vaccination data was successful with 99.1% matching. Oral rinse/gargle sample collection and 
subsequent HPV testing was feasible. Preliminary analyses found over 95% of samples to be valid 
for molecular HPV detection prevalence of oral HPV infection of 5.5% (95%CI 3.7, 8.3). It is feasible 
to recruit and follow-up dental patients largely representative / reflective of the wider population, 
suggesting it would be possible to undertake a study to investigate the prevalence, incidence, and 
determinants of oral HPV infection in dental settings.  
Key words: oral HPV, human papillomavirus, epidemiology, prevalence, feasibility study  
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Introduction 
Oropharyngeal (throat) cancer (OPC) is among the cancers with the fastest increasing incidence in 
the UK, with a near 3-fold rise in the past 15 years and incidence rates around 5 per 100,000 [1, 2, 
3]. These trends are a global phenomenon ± described as an epidemic in North America [4], with 
rapid increases also observed in Central Europe and South America following behind this curve [5]. 
Around 60% of OPC is associated with oral Human Papillomavirus (HPV) infection; likely acquired 
from genital HPV infection during oral sexual behaviour, with smoking also a strongly associated risk 
factor [6, 7]. 
HPV infection is increasingly implicated in the rising incidence of OPC [8], with HPV types 16/18 
responsible for almost all HPV-positive cases of OPC [9]. The natural history of oral HPV infection ± 
including prevalence, incidence, determinants and risk factors ± is relatively unknown. To date, the 
only large population-based study of oral HPV prevalence has been undertaken in the United States 
of America [10]. This cross-sectional study (n=5579) found an overall population prevalence of 6.9% 
and a bimodal increasing pattern with age ± a prevalence of over 7% among those in their 20s and 
30s, and a further peak of over 11% in those in their 50s and early 60s. Another cohort  (n=1688) of 
men from across the Americas found an overall prevalence of 4% [11] and 4.4% incident oral HPV 
infections in 12 months [12], and a small cohort (n=212) of male university students in the USA 
reported a prevalence of 7.5% [13]. An earlier systematic review of 18 cancer case-control studies 
worldwide found an overall prevalence of 4.5% oral HPV infection in healthy individuals (cancer-free 
control subjects) [14].  
There have been only two European studies, both small. In the first, a 9.3% prevalence was found in 
a Swedish sexual health clinic-based study (n=483), of adults aged 15-23 years, with reported high 
cervical HPV prevalence (70%) among the female participants (n=408) [15]. In the second, a 1.2% 
prevalence was reported in a small sample (n=81) study of hospital outpatients in Italy, aged 49-77 
years [16].  
Oral HPV prevalence or incidence have rarely been investigated in relation to HPV vaccination. One 
proof-of-principle study demonstrated the prevention potential of the HPV vaccination against oral 
HPV infection [17]. A recent follow-up study of the aforementioned Swedish study found a substantial 
decrease in oral HPV prevalence to 1.4% in 2013-14 from 9.3% in 2009-11 following the introduction 
of HPV vaccination between 2007 and 2014 [18].  
The National HPV Immunisation Programme in Scotland began in 12-13 year old females in 2008 as 
an intervention to reduce cervical cancer. Uptake of the HPV vaccine has been impressive, with 
sustained high levels of coverage (>90%) and a catch-up campaign, running over 3 years, which 
offered vaccination to all females aged 13-18 years old with an uptake of 66% [20]. It is feasible that 
the immunisation programmes will have an impact on infection and disease beyond those recently 
demonstrated for the anogenital tract [20]. However, there are no routine data on the population-
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based incidence and prevalence of oral HPV, nor on the impact of immunisation on oral infection or 
herd immunity in males. 
The primary aim of the HOPSCOTCH project was to test the feasibility of using dental settings, to 
undertake a population-wide (16-69 years) epidemiological study of the incidence, prevalence, and 
determinants of oral HPV infection in the Scottish population, which could ultimately allow 
assessment of the impact of the HPV vaccination programme in Scotland on oral HPV infection in 
young women and potential herd immunity in men aged 16-25 years old. The specific objectives of 
the study were to assess the feasibility and best methods of recruiting dental patients and capturing 
complete questionnaire data (including sexual history); and to examine the practical / logistical 
aspects of taking and transferring oral gargle/rinse samples from the dental facility to the Scottish 
HPV Reference Laboratory in a state suitable for assay. NHS dental facilities (including dental 
practices and dental outreach teaching centres) in Scotland are potentially ideal settings for this 
study as patients are generally healthy, attend regularly for routine dental appointments [21], and the 
oral gargle/rinse method of specimen collection is in-keeping with dental clinical activities. Dental 
teams also have a potential role in tackling rising oral/oropharyngeal cancer trends through 
prevention and early detection [22]. Moreover, Scotland is particularly well placed to conduct this 
research given the robust national health datasets and data linkage potential at the individual patient 
level, allowing individual vaccination histories to be obtained [19, 23]. 
 
Methods 
Recruitment: Baseline recruitment commenced in November 2013 and continued to March 2015. 
Potential outreach teaching centres and General Dental Practitioners (GDPs) registered with the 
Scottish Dental Practice Based Research Network (SDPBRN) as Rapid Evaluation Practices (REPs) 
were sent a Study Information Sheet and invitation letter and subsequently contacted by telephone to 
confirm suitability for participation. All potential sites were assessed for suitability regarding their 
geographical location, patient numbers/profile, wi-fi/internet accessibility and availability of private 
space. Baseline patient recruitment and data collection took place in seven sites (three outreach 
teaching centres and four GDPs). We tested recruitment and data collection conducted by Research 
Nurses in five sites (initially two, but extended to three outreach teaching centres and two GDPs) 
versus recruitment and data collection conducted entirely by the dental practice clinical team (in two 
further practices). Sites were based in NHS Greater Glasgow & Clyde (GG&C) and NHS Tayside 
Health Boards (Supporting Information File 1). Relevant personnel, including Research Nurses and 
Dental Care Teams from all participating sites, were provided with study-specific training, including 
how to handle queries and concerns raised by the questionnaire topics. Dental practice participation 
costs for each of the two models were developed based on similar items of service on the NHS 
Scotland primary care dental contract and were set in agreement with participating dentists as a 
reasonable fee for the tasks (Supporting Information File 2).  
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A paper-based participation/screening log was used to record the details of all patients screened for 
eligibility. Screened patients were either: i) sent the study invitation materials (invitation letter, 
Participant Information Sheet ± which included the information that we would not be providing 
participants with the results of the HPV test) two weeks prior to routine dental appointment; or ii) 
given the materials at the time of appointment, provided this was at least 30 minutes ahead of the 
approach for potential recruitment to the study. The method of approach varied by site, related to 
local patient appointment processes. Participating patients were assigned a study identification 
number and contact information was stored for the 6-month follow-up. For non-participants, reasons 
for non-participation, age, sex and home postcode (to assign the area-based socioeconomic 
deprivation index score ± Scottish Index Multiple Deprivation (SIMD) [24]) ± were logged.   
Informed consent was sought by Research Nurses at five sites, and by a trained Dental Nurse from 
the Dental Care Team at two sites. Consent was sought for study participation (including 6-month 
follow-up), specimen storage in the Scottish HPV Archive (Edinburgh), participation in data linkage, 
and willingness to be approached to participate in future studies.     
We developed a bespoke, web-based questionnaire with the University of Glasgow Robertson 
Centre for Biostatistics (RCB). Responses were stored directly onto the RCB secure servers. 
Participants self-completed the questionnaire via an online tablet computer in a private area (paper 
versions were also available where needed ± Supporting Information File 3 ± female questionnaire 
and File 4 ± male questionnaire). Items were based on previous studies in the field [10], along with 
the National Survey of Sexual Attitudes and Lifestyles (NATSAL) [25] and the Scottish Health Survey 
[26]. These included demographics (age, gender, ethnicity, socioeconomic status), lifestyle 
behaviours (use of tobacco, alcohol and other recreational drugs), oral health and dental care, sexual 
behaviour history / health, and history of HPV vaccination.   
Follow-up at 6-months: Participants were invited to provide follow-up data 6-months after baseline 
in one of the three following ways:          
1. Participants recruited via the Research Nurse model were followed up via specific study 
appointment sessions. All follow-up activities were conducted by a Research Nurse. 
Participants were reimbursed for travel costs. 
2. Participants recruited via the GDP model were followed up via return to the general dental 
practice setting at routine 6 monthly dental recall appointments. Follow-up activities were 
conducted by the Dental Care Team. 
3. The final one-third (sequentially) of all participants (both recruitment models) was followed up 
via a postal/online questionnaire, with self-administration of the oral gargle/rinse and posting 
of the sample. Those who failed to attend their follow-up appointment were also offered this 
option. 
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Data-linkage: The study examined the feasibility of successfully linking patient participant data to 
routine health datasets. A unique identifier relating to each participant who consented to record 
linkage to national datasets, including the Scottish Immunisation & Recall System (SIRS) and Child 
Health Schools Programme-System (CHSP-S) for HPV vaccination data, was assigned to both 
his/her consent form and questionnaire. Data linkage was performed by the Electronic Data 
Research and Innovation Service (eDRIS), Information Services Division, NHS National Services 
Scotland.  
Oral gargle/rinse specimen collection: Participants provided a bio specimen comprising a 10 ml 
oral rinse sample in saline mouth rinse at two time points, 6 months apart [10, 25]. Participants 
performed the oral gargle/rinse for 30 seconds in total ± timed on a timer application on the tablet 
computer. Specimens were sealed, labelled with the participant identifier and stored at room 
temperature or in a fridge until they were transported to the Scottish HPV Reference Laboratory 
(SHPVRL) for processing, nucleic acid (NA) extraction and molecular HPV testing. 
Specimen processing / testing: Cell pellets were obtained from 10 ml rinses via centrifugation at 
2900 r 150 X g for 15 r 2 mins., supernatants were discarded and the cellular pellets frozen in tissue 
stabilisation buffer (Qiagen, Manchester UK) pending NA extraction. NA was extracted using a 
system initially optimised for downstream HPV detection of cervical and urine samples [13] using the 
Qiagen Media Kit (Qiagen, Manchester, UK) on the MDX Platform. Yield and quality of NA were 
measured by spectrophotometry (260/280 ratios). Residual extracts after HPV genotyping were 
stored in the Scottish HPV Archive (http://www.shine.mvm.ed.ac.uk/archive.shtml) for use in 
anonymised research in the future.  
HPV genotyping: HPV amplification and genotyping were performed using a luminex based HPV 
genotyping assay, currently used for national HPV immunisation surveillance [27, 28]. This assay is 
based on amplification of a short fragment of the HPV L1 region, and delineates up to 24 high and 
low risk HPV types (including those types covered by the vaccine). It also incorporates a beta globin 
control for cellularity. HPV type specific prevalence was analysed descriptively. 
Statistical analysis of participant data was carried out using R version 3.1.1. Confidence intervals for 
the participation proportions, follow-up rates and HPV positivity percentages were calculated using 
:LOVRQ¶VPHWKRGXVLQJWKH+PLVFSDFNDJHLQ5FRQILGHQFHLQWHUYDOVDUHUHSRUWHGLQDOOFDVHs. 
Chi square tests were used to test for associations between the outcomes and demographic 
variables. Simulation tests based upon 5000 replications were used to calculate the p values. Post 
stratification weights were estimated using raking to adjust the HPV prevalence to address any 
imbalance between sample and population demographics. This was carried out using the survey 
package in R. 
Ethics statement: NHS West of Scotland Research Ethics Committee (REC) specifically approved 
this study [Reference no. 13/WS/0166:19/09/13], and NHS National Services Scotland Privacy 
Advisory Committee (PAC) [PAC37/14:4/02/15] approved the data linkage.   
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Results 
Participation rates: A total of 1212 individuals, aged 16-69, were approached to take part in the 
study from seven centres in two health board areas ± NHS GG&C and NHS Tayside. Of these, 59% 
were female compared to the Scottish population of which 51% in this age-group are female [29]. 
The age distribution among the individuals who were approached was also an under-representation 
of those in the 16-25 age group (12% of those approached and 19% of population) and the 26-39 
age group (20% of those approached and 25% of the population). There is a corresponding slight 
over-representation in the older ages (Table 1). 
In total, 402 individuals agreed to participate in the study giving an overall participation rate of 33.1% 
with no imbalance in participation rates between men and women. Among the 1072 with known age, 
participation was significantly associated with age (p=0.010) and was lower among those aged 16-
25. There was no apparent association (p=0.827) with participation and SIMD (Table 1).  
Table 1 Participation rates by demographic and research model characteristics 
 
 
n ± number; CI ± Confidence Interval 
SIMD ± Scottish Index of Multiple Deprivation 
GDP ± General Dental Practice 
GG&C ± Greater Glasgow & Clyde   
Variable Category Approached n Participated n %
Overall 1212 402 33.2 30.6 35.9
Gender Male 502 161 32.1 28.1 36.3
Female 710 241 33.9 30.6 37.5
Age 16-25 146 42 28.8 22.0 36.6
26-39 245 106 43.3 37.2 49.5
40-49 255 84 32.9 27.5 38.9
50-59 243 90 37.0 31.2 43.3
60-69 183 80 43.7 36.7 51.0
Missing 140 0 0.0 0.0 2.7
SIMD 1 (most deprived) 280 90 32.1 26.9 37.8
2 157 59 37.6 30.4 45.4
3 177 61 34.5 27.9 41.7
4 279 92 33.0 27.7 38.7
5 (least deprived) 265 90 34.0 28.5 39.9
Incomplete Postcode 40 6 15.0 7.1 29.1
Missing Postcode 14 4 28.6 11.7 54.6
Centre Teaching/outreach 1 - Tayside 102 17 16.7 10.7 25.1
GDP 1 - Tayside 176 34 19.3 14.2 25.8
GDP 2 - Tayside 268 104 38.8 33.2 44.8
Teaching/outreach 1 - GG&C 369 130 35.2 30.5 40.2
GDP 1 - GG&C 167 60 35.9 29.0 43.4
GDP 2 - GG&C 101 45 44.6 35.2 54.3
Teaching/outreach 2 - Tayside 29 12 41.4 25.5 59.3
Recruitment model Research Nurse 935 323 34.5 31.6 37.7
Dental Team 277 79 28.5 23.5 34.1
Setting Teaching/outreach 500 159 31.8 27.9 36.0
General Dental Practice (GDP) 712 243 34.1 30.7 37.7
    95% CI
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There were significant differences among the participation rates according to research site - 
(p<0.0001), with relatively low participation in two centres (GDP1 ± Tayside, and outreach teaching 1 
± Tayside). Participation was not significantly (p=0.072) associated with the use of a Research Nurse 
as opposed to a Dental Care Team. Similarly, it was not associated (p=0.432) with the type of dental 
setting (Table 1). Reasons for non-participation were documented for 81% of the 811 non-responders 
(Table 2). The main reason noted for non-participation was patient refusal (31.6%). 
 
Table 2  Reasons for non-participation 
 
 
 
Of those who had agreed to participate (n=402): (a) all participants had initialled the box on the 
consent form indicating they had understood the Participant Information Sheet and agreed to 
participate in the baseline and 6-month follow-up; (b) 16 (3.9%) did not give consent for the data 
linkage element of the study; (c) 23 (5.7%) participants did not wish to be contacted about future 
studies. The Research Nurse model was more effective in terms of achieving the target recruitment 
numbers on time in three of the four sites (26 recruiting weeks, 30 calendar weeks), while the Dental 
Care Team model did not reach the target despite recruiting in almost twice the number of recruiting 
weeks (49 recruiting weeks, 55 calendar weeks). The average cost per recruitment was substantially 
lower in the Dental Care Team model (£26.23) ± under half those associated with the Research 
Nurse (£66.46).  
Questionnaire data: A total of 390 participants (from 402 who consented) completed the 
questionnaire (n=210, 53.8% electronically, and n=180, 46.2% on a paper version); 263 (67.4%) 
participants completed all 30 questions which should have been answered by everyone, 354 (90.8%) 
omitted less than 2 questions. The most non-responses (12.1%) were for the income question (Table 
3). Only 7 (1.8%) participants did not answer the question about recreational drug use (Table 4). 
Similarly there were low levels of missing data on the sexual health questions for both men and 
women and there was only one woman who did not answer the HPV vaccination question. Most 
Reason for Non Participation n %
Did not want to participate 256 31.6
Did not attend appointment 132 16.3
Did not have time 107 13.2
Did not receive Patient Information Sheet 43 5.3
Dentist refused 7 0.9
Inability to read English 5 0.6
Did not want to complete questionnaire 4 0.5
Concerned about NOT receiving HPV test results 2 0.2
Did not want to complete oral rinse/gargle 2 0.2
Did not want to commit to 6-month follow-up 1 0.1
Other 96 11.8
Not Known 156 19.2
Total 811
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participants (99.0%) answered some of the sexual history questions, and 331 ± 136 men / 195 
women ± (84.9%) answered all seven of the questions for men and all eight for women (Table 5). 
While we had high responses to the sexual behaviour and health questions, 35.7% of males and 
39.6% of females reported that they were uncomfortable with the questions on sexual activity in 
feedback items at the end of the questionnaire.  
 
The self-report vaccine data were comparable to the health administrative datasets. Data linkage of 
our study data to the Community Health Index (CHI) number (the unique identifier which is a 
population register used to register all patients in Scotland with a family doctor) was successful on 
99.7% (n=384) of the 385 participants ZKR¶VGDWDZHUHVXEPLWWHGWRISD ± all of whom had 
consented for data linkage. For the purposes of preliminary feasibility, linkage to the SIRS database 
was tested. Of the 375 individuals who completed the questionnaire and linked to SIRS database, 15 
had received the HPV vaccination (13 had all three doses, one had two doses, and one had one 
dose). There were no HPV vaccination records for men in the SIRS data. Among the 221 
questionnaires from female participants, 18 reported having had the HPV vaccine (16 reported 
having had all three doses, 2 had one or two doses), 202 reported no HPV vaccine, with 1 missing 
value. Three women stated that they had the HPV vaccine (2 with all three doses and 1 with one or 
two doses) but there is no corresponding record in SIRS; these three women were aged between 35-
50 years and it is unlikely that they received the vaccine. Among the 21 women aged 16-25 there 
was an exact match between the questionnaire and SIRS for 17.  Of the remainder, one reported that 
she had received three doses but has only one record in the SIRS data, and two stated that they had 
three doses but there is no record in SIRS.   
Table 3 Participant self-report sociodemographic characteristics 
 
Number Male Female
Characteristic Responding % (n=158) % (n=232)
Ethnicity White 383 93.5% (143) 95.7% (220)
Mixed 0.7% (  1) 0.0% (  0)
Asian; Asian Scottish or Asian British 2.6% (  4) 2.2% (  5)
African 1.3% (  2) 1.3% (  3)
Any other ethnicity 2.0% (  3) 0.9% (  2)
Missing n 5 2
Education level Primary School 377 0.0% ( 0) 0.9% ( 2)
Secondary School 15.5% (23) 21.8% (50)
Further Education/Technical College 39.2% (58) 29.7% (68)
University 40.5% (60) 40.6% (93)
Some other type of college 4.7% ( 7) 7.0% (16)
Missing n 10 3
Marital status Never married and never registered a same-sex civil partnership 370 28.9% (43) 34.8% (77)
Married 58.4% (87) 40.3% (89)
Separated but still legally married 2.0% ( 3) 5.4% (12)
Divorced 8.1% (12) 12.2% (27)
Widowed 1.3% ( 2) 4.5% (10)
In a registered same-sex civil partnership 1.3% ( 2) 2.7% ( 6)
Missing n 9 11
Annual income (£) Nil or loss 343 1.4% ( 2) 2.0% ( 4)
1-9,999 10.5% (15) 18.5% (37)
10k-19,999 20.3% (29) 26.5% (53)
20k-29,999 14.7% (21) 16.0% (32)
30k-39,999 19.6% (28) 13.5% (27)
>40k 33.6% (48) 23.5% (47)
Missing n 15 32
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Table 4 Participant self-report lifestyle behaviours 
 
 
  
Number Male Female
Behaviour Responding % (n=158) % (n=232)
Alcohol ever Current 382 85.2% (132) 86.3% (196)
Former 10.3% ( 16) 8.4% ( 19)
Never 4.5% (  7) 5.3% ( 12)
Missing n 3 5
Alcohol frequency Monthly or less 357 19.7% (29) 32.9% (69)
2 - 4 times per month 19.7% (29) 34.8% (73)
2 - 3 times per week 40.1% (59) 19.5% (41)
4+ times per week 20.4% (30) 12.9% (27)
Missing n 11 22
Units per day 1-2 341 20.7% (29) 37.3% (75)
3-4 29.3% (41) 23.4% (47)
5-6 11.4% (16) 16.4% (33)
7-9 12.1% (17) 10.0% (20)
10+ 26.4% (37) 12.9% (26)
Missing n 18 31
> recommended Never 349 20.5% (30) 31.0% (63)
units Less than monthly 28.8% (42) 37.4% (76)
Monthly 19.2% (28) 18.7% (38)
Weekly 26.0% (38) 11.8% (24)
Daily or almost daily 5.5% ( 8) 1.0% ( 2)
Missing n 12 29
Smoking Yes 385 25.6% ( 40) 27.5% ( 63)
No 74.4% (116) 72.5% (166)
Missing n 2 3
Recreational drugs Yes 383 38.7% ( 60) 27.6% ( 63)
No 61.3% (95) 72.4% (165)
Missing n 3 4
Cannabis Yes 389 35.7% ( 56) 22.0% ( 51)
No 64.3% (101) 78.0% (181)
Missing n 1 0
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Table 5 Participant self-report sexual behaviour and health history 
 
Male Female
Behaviour % (n=158) % (n=232)
Ever sex Yes 381 99.3% (152) 98.2% (224)
No 0.7% (1) 1.8% (4)
Missing n 5 4
Vaginal sex Yes 367 98.7% (147) 97.7% (213)
No 1.3% (2) 2.3% (5)
Missing n 8 10
Age first vaginal sex <=15 336 20.0% ( 28) 15.8% ( 31)
(years) 16-20 62.9% ( 88) 73.0% (143)
>20 17.1% ( 24) 11.2% ( 22)
Missing n 17 32
No. vaginal sex <=2 322 16.3% (21) 34.7% (67)
partners 3-5 21.7% (28) 29.0% (56)
6-10 27.9% (36) 19.2% (37)
>10 34.1% (44) 17.1% (33)
Missing n 28 35
Sexual history Only with females 375 93.2% (138) 0.0% (  0)
More often with females 3.4% (  5) 3.5% (  8)
About equally often with females and males 0.7% (  1) 0.0% (  0)
More often with males 2.7% (  4) 6.6% ( 15)
Only with males 0.0% (  0) 88.1% (200)
Only ever with females and never with males 0.0% (  0) 0.9% (  2)
I have never had any sexual experience with anyone at all 0.0% (  0) 0.9% (  2)
Missing n 10 5
Oral sex with men Yes 366 5.3% (  8) 89.3% (192)
No 94.7% (143) 10.7% (23)
Missing n 6 13
Oral sex with men 1 185 0.0% ( 0) 34.5% (61)
no. of life partners 2 12.5% ( 1) 20.9% (37)
3-5 25.0% ( 2) 24.9% (44)
>5 62.5% ( 5) 19.8% (35)
Missing n 0 15
Oral sex with men 0 183 16.7% (  1) 36.7% ( 65)
no. of partners in 1 33.3% (  2) 58.2% (103)
past year >1 50.0% (  3) 5.1% (  9)
Missing n 2 15
Oral sex with women Yes 374 90.7% (137) 6.3% ( 14)
No 9.3% (14) 93.7% (209)
Missing n 6 5
Oral sex with women <=2 138 33.1% (41) 71.4% (10)
no. of life partners 3-5 32.3% (40) 14.3% ( 2)
>5 34.7% (43) 14.3% ( 2)
Missing n 13 0
Oral sex with women 0 140 23.8% (30) 42.9% ( 6)
no. of partners in 1 63.5% (80) 50.0% ( 7)
past year >1 12.7% (16) 7.1% ( 1)
Missing n 11 0
Anal sex with men Yes 366 4.7% (  7) 24.1% ( 52)
No 95.3% (143) 75.9% (164)
Missing n 7 12
Anal sex with women  Yes 149 36.2% (54)
No 63.8% (95)
Missing n 8
Sexually transmitted Yes 380 10.9% ( 17) 14.7% ( 33)
infection No 89.1% (139) 84.8% (190)
Don't remember 0.0% (  0) 0.4% (  1)
Missing n 2 8
Genital warts Yes 382 7.1% ( 11) 7.0% ( 16)
No 92.2% (142) 91.7% (209)
Don't remember 0.6% (  1) 1.3% (  3)
Missing n 4 4
HIV Test Yes 383 20.8% ( 32) 18.8% ( 43)
No 76.6% (118) 75.5% (173)
Maybe/not sure 2.6% (  4) 5.7% ( 13)
Missing n 4 3
HIV Result Negative 75 96.9% (31) 100.0% (43)
Positive 3.1% (1) 0% (0)
Missing n 0 0
HPV Vaccine Yes (3 doses) 231 7.4% ( 17)
Yes (1/2 doses) 0.9% (  2)
No 91.8% (212)
Missing n 1
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Follow-up at 6 months: Follow-up is primarily assessed among the 380 participants who had a valid 
baseline oral gargle/rinse specimen, as the principal aim of the follow-up is in the determination of 
new/incident acquisitions of oral HPV among participants who were negative at baseline and 
clearance of HPV among participants who were positive for HPV at baseline. Participants who had a 
follow-up oral specimen submitted to SHPVRL were considered to have satisfied the conditions for a 
successful follow-up. Overall follow-up rate was 61.6%, with similar rates among men and women. 
Follow-up was significantly better among older patients (p<0.0001). There was no evidence 
(p=0.186) to suggest that follow-up was associated with deprivation of the participant (Table 6). The 
evidence suggested that follow-up was better with Research Nurses (p=0.023) with a rate of 64.3% 
compared to 48.5% with Dental Care Team model. Follow-up in GDPs was slightly better than 
outreach teaching centres but not statistically different (p=0.159).  Follow-up by appointment in either 
setting or by either recruitment model had substantially higher (p<0.0001) follow-up success (86.6%) 
compared to postal follow-up (39.7%). 
 
Table 6 Follow-up participant characteristics 
 
 
HPV testing process: Generally, operational processes between source collection points and the 
central testing laboratory were good with few significant issues. Of the samples received at SHPVRL, 
only 11 could not be processed for HPV testing: 7/11 were discarded due to a packaging error where 
Variable Category Follow-up HPV Test %                   95% CI
Overall 380 234 61.6 56.6 66.3
Gender Male 154 94 61.0 53.2 68.4
Female 226 140 61.9 55.5 68.0
Age 16-25 39 18 46.2 31.6 61.4
26-39 96 44 45.8 36.2 55.8
40-49 81 49 60.5 49.6 70.4
50-59 83 59 71.1 60.6 79.7
60-69 81 64 79.0 68.9 86.5
SIMD 1 (most deprived) 89 47 52.8 42.5 62.8
2 57 41 71.9 59.2 81.9
3 55 32 58.2 45.0 70.3
4 89 57 64.0 53.7 73.2
5 (least deprived) 86 55 64.0 53.4 73.3
Centre Teaching/outreach 1 - Tayside 17 12 70.6 46.9 86.7
GDP 1 - Tayside 26 11 42.3 25.5 61.1
GDP 2 - Tayside 98 77 78.6 69.5 85.5
Teaching/outreach 1 - GG&C 128 72 56.3 47.6 64.5
GDP 1 - GG&C 60 36 60.0 47.4 71.4
GDP 2 - GG&C 40 21 52.5 37.5 67.1
Teaching/outreach 2 - Tayside 11 5 45.5 21.3 72.0
RecruitmenResearch Nurse 314 202 64.3 58.9 69.4
Dental Team 66 32 48.5 36.8 60.3
Setting Teaching/outreach 156 89 57.1 49.2 64.6
General Dental Practice (GDP) 224 145 64.7 58.3 70.7
Follow Up MAppointment 179 155 86.6 80.8 90.8
Post 199 79 39.7 33.2 46.6
Unknown 2 0 0.0 0.0 65.8
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the transit receptacle was used to contain the sample instead of the primary (inner) tube and 4/11 
were labelled inadequately. These issues related to 2 tranches of samples rather than 11 separate 
errors. 
  
The automated NA extraction procedure, initially designed for cervical cytology samples, was 
amenable to oral wash pellets and <5% showed clogging/blocking on the automated platform. This 
level was manageable from a laboratory-process point of view. Quantity of extracted NA varied 
according to sample and associated cellularity. Quantitative assessment of showed that the mean NA 
yield was 64ng/ul (range 27ng/ul to 130ng/ul). Yield was not affected according to whether the 
sample was transported as a postal kit or via the practice and, as described, was more dependent on 
the individual sample. Purity of the NA as measured by 260/280 absorbance ratios showed between 
sample variation; however, adequate quality for the key downstream application [HPV PCR testing] 
was evidenced by amplification of the cellular in-house control (beta globin) in 98% of samples.  
 
HPV prevalence and diversity: The present study was not powered to examine HPV prevalence of 
HPV types including in subgroups or in relation to risk associations.There were 380 participants with 
an unequivocal HPV test result at baseline (Table 7). At baseline, 21 participants were HPV positive, 
giving a prevalence of 5.5% (95%CI 3.6%, 8.3%). In relation to the HPV types detected at baseline, 
17 samples had mono infections, 4 had dual infections and one contained multiple-infection with 5 
types. A total of 14 samples contained at least one high-risk HPV type, whereas 5 samples contained 
low-risk types only (3 x HPV 42, 1 x HPV 44, 1 x HPV 42 & 44) and 2 samples types of intermediate 
risk (1 x HPV 53, 1 x HPV 66).  HPV 16 was the most commonly detected infection and was evident 
in 12/17 samples; other HR-HPV types detected were HPV 39, HPV 56, HPV 58 and HPV 59 either 
as mono infections or as part of a  multiple infection.  
 
Oral HPV positivity did not vary with gender but there is a suggestion of an association with age 
(p=0.081) and with deprivation, (p=0.037). Oral HPV positivity was greatest in the 26-39 age-group 
where the rate was 10.4% (95%CI 5.8%, 18.1%) compared to a rate of 2.6% (95%CI 0.1%, 13.2%) in 
the 16-25 age group.  
Out of the 380 who gave a valid oral swab at baseline, 234 had a valid swab at follow-up, 61.6% 
(95% CI 56.6%, 66.3%). Among those with both a baseline and follow up HPV result, 4 out of 223 
HPV negative at baseline acquired HPV, 1.8% (95% CI 0.7%, 4.5%). There were 11 HPV positive 
individuals at baseline and 8 were clear of HPV at follow-up, giving a clearance percentage of 72.7% 
(95% CI 43.3%, 90.3%). 
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Table 7 Oral HPV Prevalence 
 
 
 
Discussion 
In summary, our multidisciplinary research group has demonstrated feasibility of recruiting 
participants using dental care facilities, a centralised laboratory (SHPVRL), and data-linkage 
resources, to undertake epidemiological studies of oral HPV infection. The experience and data 
gained now make us well placed to design and implement a population study which would measure 
the impact of the HPV vaccine on oral HPV among women and assess the implications for extending 
the vaccine to boys.  
We achieved an overall participation rate of 33.1%, which was somewhat lower than the 67% 
participation rate in the National Health and Nutrition Survey (NHANES) used in the US oral 
prevalence study [10], but is higher than the approximate 10% reported in the Swedish study [15], 
and participation rates are unreported in other studies [11, 13, 16]. However, our recruitment strategy 
was to opportunistically approach sequential patients attending dental practices (for the purposes of 
dental care), while the NHANES study involved targeted approaches to households and home-based 
interviews. Lower proportions of younger patients were recruited than anticipated, despite dental 
registration being high for this group [21]. The 16-25 year age-group was particularly important given 
that women from this group will have had the opportunity for HPV vaccination as part of the national 
programme. The imbalance of more female to male patients approached was also interesting. This 
was similar to data in the British Household Panel Survey 2008 from Scottish responders, which 
showed that females (71%) were more likely to report having a dental check-up than males (63%), 
and similarly for NHS dental check-ups: females 54% and males 44% [30]. NHS dental practices in 
Variable Category Total HPV prevalence n %                    95% CI
Overall 380 21 5.5 3.6 8.3
Gender Male 154 8 5.2 2.7 9.9
Female 226 13 5.8 3.4 9.6
Age 16-25 39 1 2.6 0.1 13.2
26-39 96 10 10.4 5.8 18.1
40-49 81 5 6.2 2.7 13.6
50-59 83 1 1.2 0.1 6.5
60-80 81 4 4.9 1.9 12.0
SIMD 1 (most deprived) 89 9 10.1 5.4 18.1
2 57 1 1.8 0.1 9.3
3 55 5 9.1 3.9 19.6
4 89 4 4.5 1.8 11.0
5 (least deprived) 86 1 1.2 0.1 6.3
Missing 4 1 25.0 1.3 69.9
HPV Acquisition since baseline 223 4 1.8 0.7 4.5
HPV Clearance since baseline 11 8 72.7 43.4 90.3
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Scotland seem to be a potentially good way to access representative population. In terms of both 
their location and the profile of registered patients ± with limited differences by region, age, sex, and 
socioeconomic compared to the Scottish population. There is now over 90% of the population 
registered in 2014, 70% of whom attended in previous 2 years [21]. 
The consent rate to the data linkage component (96%) was substantially higher than anticipated or 
observed elsewhere ± a systematic review and meta-analysis of the international literature estimated 
67% consent rate to use linkage to medical records [31]. Moreover, the data linkage could be used to 
validate self-reported HPV-vaccination history, but with greater detail on timings and doses available 
from the linked data than the self-report information. 
To our knowledge this was the first observational epidemiological studies in Scotland to recruit 
patients through dental settings with support of Research Nurses. While both the Research Nurses 
and Dental Teams faced the same challenges in terms of converting patient approaches to study 
participants, the Research Nurses were largely able to work more intensively, recruit more 
participants, and meet their targets on time. Dental Care Teams managed to recruit participants at 
the same patient participation rate, but were not able to recruit sufficient numbers in the allotted time-
frame. The higher costs for the Research Nurse model were due to them being employed and their 
salary costs being paid directly for this study. They were then deployed to work within the different 
dental settings. The Dental Care Teams were fitting this study into their clinical daily practice routine 
and were compensated accordingly on an individual participant recruitment basis which was based 
on payment of similar tasks on their contract. Completion of the questionnaire on the tablet computer 
was disappointingly much lower than anticipated. The reasons were that one centre offered the paper 
version as an option rather than as a back-up, and there were technical reasons, mainly related to 
internet connectivity issues in two centres, which could be addressed prior to a larger study. 
Postal follow-up, in which patients provided their own oral gargle/rinse specimen and posted it (with 
the online/postal questionnaire) was less effective (36.4%) than a follow-up appointment, However 
this response was much higher than that observed in an earlier Scottish survey to facilitate HPV 
vaccine monitoring where response rate to a self-taken urine or vaginal swab was (13.2%) [32]. It is 
worth noting that recruitment did not seem to be affected by the fact that we were not going to 
feedback HPV test results.  
Participants were able to complete a questionnaire covering a wide-range of factors including 
demographic, socioeconomic, lifestyle, and sexual behaviour/health. While a third of participants 
gave feedback that they were uncomfortable with the sexual activity questions, completion rates were 
high, and participants were able to disclose risk behaviours. Capture of this information may have 
been facilitated by self-completion in a private area or perhaps (for over a half of participants) by the 
online questionnaire.  
In terms of sexual history, we were able to access a significantly at-risk sample. For example, 39% of 
male participants reported recreational drug use, 34% of males reported >10 partners, 36% of males 
16 
 
reported insertive anal sex with a female partner and 24% of women reported receptive anal sex. The 
proportions reporting >10 partners is broadly similar to those reported by the NATSAL study [23]. In 
addition, 15% of women reported a previous STI. This risk behaviour profile carried into reported 
smoking and alcohol intake, with smoking prevalence (males 26%, females 28%) slightly higher than 
the Scottish population (males 25%, females 24%), and alcohol abstinence (males 4%, females 5%) 
lower than the Scottish population (males 12%, females 17%) [24]. There were insufficient data to 
look at risk associations of sociodemographic and behavioural factors with oral HPV prevalence or 
incidence. 
Our preliminary estimate of oral HPV prevalence (5.5%; 95%CI 3.6, 8.3) is remarkably in-keeping 
with the overall prevalence in the US population (6.9%; 95%CI 5.7, 8.3) [10], and the pooled estimate 
from the systematic review and meta-analysis (4.5%; 95%CI 5.7, 4.1) [14]. We did not have sufficient 
power in our study to produce precise estimates of prevalence in different strata or subgroups, 
although there was a tendency for higher prevalence in 26-39 years olds (10.4%; 95%CI 5.8%, 18.1). 
 
Conclusions 
Our study demonstrates that it is feasible to investigate the prevalence, incidence, and determinants 
of oral HPV infection in dental settings. We now know what resources and methods are needed to 
expand this approach to assess the impact of the school-based HPV vaccination programme in 
Scotland on oral HPV in girls/women who have received the vaccine and to examine if there has 
been any herd immunity in boys/men. Crucially we have sufficient data to power a full-population 
approach. We have provided the first preliminary estimate of oral HPV prevalence in the Scottish 
population. In our preliminary analysis we found an overall prevalence of oral HPV infection of 5.5% 
and a higher prevalence among 26-39 year olds of 10.4%. 
We demonstrated that the Research Nurse recruitment model was more effective than Dental Care 
Teams in terms of baseline and follow-up recruitment and meeting recruitment targets on time, but 
that the former model was more expensive.  
To undertake a fully powered study to assess the impact of the HPV vaccination programme in 
Scotland on oral HPV infection in men and women, we would need to enhance recruitment of 16-25 
year olds. This could be established in dental settings serving populations with a high proportion of 
young people, including community and Further/Higher education settings. 
We have also shown that the boundaries of the nature of research undertaken in dental settings can 
be stretched beyond current traditional dental care and research remits. This points to the importance 
of further research into  barriers and facilitators to implement other risk factor assessment / 
prevention, screening, and care activities not necessarily associated with current practice (eg: 
smoking/alcohol counselling, diabetes/HIV screening, or further clinical prevention interventions).  
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